Criteria and treatment of failing responses to imatinib in chronic myeloid leukemia;Critères et traitement des réponses insuffisantes à l'imatinib dans la leucémie myéloïde chronique

Hematologie

Volumn 12, Issue 5 SPEC. ISS., 2006, Pages 19-25

  Rousselot, Philippe ^a  

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; DASATINIB; HOMOHARRINGTONINE; IMATINIB; NILOTINIB; PROTEIN INHIBITOR;

BLOOD TRANSFUSION; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; DRUG MECHANISM; GENETIC TRANSCRIPTION; HUMAN; LABORATORY TEST; MEDICAL RESEARCH; MOLECULAR BIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT RESPONSE;

EID: 33845917015     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Druker BJ. Circumventing Resistance to Kinase inhibitor Therapy. N Engl J Med 2006; 354: 2594-6.
2. Baccarani M, Russo D, Rosti G, Martinelli G. Interferon-alfa for chronic myeloid leukemia. Semin Hematol 2003; 40: 22-33.
3. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al., International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-32.
4. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37.
5. Bories D, Devergie A, Gardembas-Pain M, Kuentz M, Legros L, Mahon FX, et al. Stratégies thérapeutiques et recommandations pour la prise en charge des patients atteints de leucémie myéloïde chronique. Hématologie 2003; 9: 497-512.
6. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-20.
7. Hughes TP, Branford S, Reynolds J, Koelmeyer R, Seymour J, Taylor K, et al. Maintenance of imatinib dose intensity in the first six months of therapy for newly diagnosed patients with CML is predictive of molecular response, independent of the ability to increase dose at a later point. Blood 2006; 106: abstract 164.
8. Goldman JM, Hughes T, Radich J, Branford S, Hochhaus A, So C, et al. Continuing reduction in level of residual disease after 4 years in patients with CML in chronic phase responding to first-line imatinib (IM) in the IRIS Study. Blood 2006; 106: abstract 163.
9. Terré C, Eclache V, Rousselot P, Imbert M, Charrin C, Gervais C, et al., France intergroupe pour la leucémie myéloïde chronique. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004; 18: 1340-6.
10. Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005; 105: 2281-6.
11. Guilhot F, Larson R, O'Brien S, Druker BJ, On behalf of IRIS Study Group. Long term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemiain chronic phase (CML-CP): the 5 years update of from the IRIS study. Haematology 2006; 19: abstract 466.
12. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006; 20: 1767-73.
13. Frank O, Brors B, Fabarius A, Li L, Haak M, Merk S, et al. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia 2006; 8: 1400-7.
14. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-42.
15. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935-42.
16. Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Muller C, et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004; 5: 55-60.
17. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-51.
18. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-41.
19. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-42.
20. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873-8.
21. Marin D, Goldman JM, Olavarria E, Apperley JF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood 2003; 102: 2702-3.
22. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faded S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 101: 473-5.
23. Levy V, Zohar S, Bardin C, Vekhoff A, Chaoui D, Rio B, et al. A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br J Cancer 2006; 95: 253-9.
24. Rousselot P, De Sarrazin A, Cayuela JM, Maarek O, Gaub MP, Maloisel F. Homoharringtonine is associated with a high proportion of hematologic response in CML patients with hematologic failure to imatinib. Haematology 2006; 19: abstract 167.
25. Michallet M, Maloisel F, Delain M, Hellmann A, Rosas A, Silver RT, et al. PEG-Intron CML Study Group. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia 2004; 18: 309-15.
26. Rousselot P, Cony-Makhoul P, Sotto JJ, Rio B, Guy H, Tilly H, et al. Randomized comparrison of imatinib combination therapies in newly diagnosed chronic myelogenous leukaemia patients: design and first interim analysis of a phase III trial. Haematology 2006; 19: abstract 1026.
27. Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006; 108: 2037-40.
28. Reiffers J, Goldman J, Meloni G, Cahn JY, Gratwohl A. Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant 1994; 14: 407-10.
29. Pui CH, Relling MV, Evans WE. Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002; 15: 741-56.
30. Hochhaus H, Kantarjian H, Shah N, Rosti G, Cervantes F, Facon T, et al. A phase II study of dasatinib in patients with chronic phase chronic myelogenous leukaemia (CML_CP) who are resistant or intolerant to imatinib: results of the CA180013 "START-C" study. Haematological 2006; 19: abstract 467.
31. Nicolini FE, Corm S, Le QH, Sorel N, Hayette S, Bories D, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French Intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006; 20: 1061-6.
32. Bradeen HA, Eide CA, O'hare T, Johnson KJ, Willis SG, Lee FY, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006; 108: 2332-8.